Akıllı Rabia, Demir Mesut
Department of Cardiology, Çukurova University Faculty of Medicine, Adana, Turkey.
Turk Kardiyol Dern Ars. 2017 Sep;45(Suppl 4):15-23. doi: 10.5543/tkda.2017.27632.
Atrial fibrillation (AF) is the most common persistent cardiac arrhythmia and causes mortality in the community. Cardioversion and catheter ablation are frequently used methods for rhythm control. Oral anticoagulants have been used for many years in the prevention of thromboembolic complications in patients with AF. Both cardioversion and catheter ablation have been associated with certain complication risks especially thromboembolism, which can be significantly reduced by adequate anticoagulation. In this review, we discuss the efficacy and safety parameters of continuous rivaroxaban treatmentn compared with dose-adjusted vitamin K antagonist therapy in patients who were planned to undergo cardioversion and catheter ablation according to the data of X-VERT and VENTUREAF trials.
心房颤动（AF）是最常见的持续性心律失常，可导致社区人群死亡。心脏复律和导管消融是常用的节律控制方法。口服抗凝剂多年来一直用于预防房颤患者的血栓栓塞并发症。心脏复律和导管消融都存在一定的并发症风险，尤其是血栓栓塞，充分抗凝可显著降低这种风险。在本综述中，我们根据X-VERT和VENTURE AF试验的数据，讨论在计划进行心脏复律和导管消融的患者中，与剂量调整的维生素K拮抗剂治疗相比，利伐沙班持续治疗的有效性和安全性参数。
